Equity Profile

COLL

Collegium Pharmaceutical, Inc.

Health CarePharmaceuticals$1.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COLL Q2-2026 Earnings Preview

Context

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions. With a market cap of $1 billion, it plays a significant role in the pharmaceuticals industry, particularly as demand for effective pain relief options continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+18.86%

Avg Stock Reaction

+4.02%

Last Quarter Recap

In Q1 2026, Collegium reported an EPS of $1.76, significantly beating expectations by 43.09%. The stock reacted positively, gaining 7.72% the following day.

Management Promises & Guidance

Continued focus on innovative pain management solutions.
Commitment to expanding market presence and product offerings.

Expectations

Wall Street Expectations

Overall expectations for Collegium's upcoming earnings are cautiously optimistic, given its strong performance in previous quarters.

Bull Case

If Collegium continues its trend of beating EPS estimates, it could see a significant stock price increase, similar to past reactions.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it may face a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial in determining market sentiment.

How does Collegium plan to expand its market presence in the coming quarters?

Investors will be looking for specific strategies or commitments that could drive future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Collegium's ability to innovate in pain management, leading to stronger-than-expected revenue growth.

Supporting Evidence

Collegium has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a smaller move than historical averages, suggesting potential for a larger surprise.

Key Risk

If EPS comes in below $1.50, it could signal deeper issues with growth and profitability.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Collegium can maintain its strong performance or if it will face challenges in sustaining growth.

Bull Confirmed If

An EPS of $1.80 or higher would confirm the bullish case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.50 would support the bearish case, raising concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±2.2%

Historical Avg

±4.9%

Pricing rich

The options market is pricing a modest move around the earnings report, suggesting that investors are uncertain about significant changes.

Options are pricing ±11.9% while COLL has averaged ±4.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Collegium beats expectations, history suggests the stock could rise by around 4.02%, confirming strong operational health.

In-Line / Cautious

A cautious inline report may lead to muted reactions, as investors await further guidance on future growth.

Miss

If the company misses expectations, the stock could decline, with historical patterns suggesting an average drop of around 4.02%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the pain management sector.
2Details on market expansion strategies and potential partnerships.
3Insights into competitive positioning against other pharmaceutical companies.
4Management's outlook on regulatory challenges and opportunities.
5Clarification on any changes in production or supply chain dynamics.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COLL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+18.86%

Avg Stock Reaction

+4.02%

Last Quarter Recap

In Q1 2026, Collegium reported an EPS of $1.76, significantly beating expectations by 43.09%. The stock reacted positively, gaining 7.72% the following day.

Management Promises & Guidance

Continued focus on innovative pain management solutions.
Commitment to expanding market presence and product offerings.

Expectations

Wall Street Expectations

Overall expectations for Collegium's upcoming earnings are cautiously optimistic, given its strong performance in previous quarters.

Bull Case

If Collegium continues its trend of beating EPS estimates, it could see a significant stock price increase, similar to past reactions.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it may face a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial in determining market sentiment.

How does Collegium plan to expand its market presence in the coming quarters?

Investors will be looking for specific strategies or commitments that could drive future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Collegium's ability to innovate in pain management, leading to stronger-than-expected revenue growth.

Supporting Evidence

Collegium has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a smaller move than historical averages, suggesting potential for a larger surprise.

Key Risk

If EPS comes in below $1.50, it could signal deeper issues with growth and profitability.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Collegium can maintain its strong performance or if it will face challenges in sustaining growth.

Bull Confirmed If

An EPS of $1.80 or higher would confirm the bullish case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.50 would support the bearish case, raising concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±2.2%

Historical Avg

±4.9%

Pricing rich

The options market is pricing a modest move around the earnings report, suggesting that investors are uncertain about significant changes.

Options are pricing ±11.9% while COLL has averaged ±4.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Collegium beats expectations, history suggests the stock could rise by around 4.02%, confirming strong operational health.

In-Line / Cautious

A cautious inline report may lead to muted reactions, as investors await further guidance on future growth.

Miss

If the company misses expectations, the stock could decline, with historical patterns suggesting an average drop of around 4.02%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the pain management sector.
2Details on market expansion strategies and potential partnerships.
3Insights into competitive positioning against other pharmaceutical companies.
4Management's outlook on regulatory challenges and opportunities.
5Clarification on any changes in production or supply chain dynamics.